UK damages award could chill use of injunctions in infringement cases
This article was originally published in SRA
Executive Summary
Before applying for an interim injunction in the UK, pharmaceutical companies may want to take note of a recent Court of Appeal ruling that upheld a £27m damages award made to Krka and Consilient in compensation for delays to the launch of their generic version of AstraZeneca's Nexium (esomeprazole).